Global Vaccine Reach IVI operates with regional offices and collaborating centers across multiple continents (Seoul HQ, Europe, Africa, and partnerships with institutions in Bhutan, Burkina Faso, Ghana, Ethiopia, Nepal, Madagascar, and more), indicating potential for multinational collaborations, joint ventures, and funding opportunities across LMICs.

Public-Private Partnerships Recent press activity highlights collaborations with CEPI, SK bioscience, PAHO, Gavi, WHO, and CDC, signaling strong appetite for joint development, co-funding, and technology transfer agreements that can be leveraged for accelerated vaccine programs and market access.

Low-Cost Vaccine Leadership IVI has a track record of delivering affordable vaccines, including the world’s first low-cost oral cholera vaccine and a WHO pre-qualified typhoid conjugate vaccine, presenting opportunities to pitch expansion of cost-effective manufacturing, distribution licenses, and rotor-scale procurement deals for low-resource markets.

kenya Expansion New Country Office in Nairobi and partnership with Kenyan research institutions indicate a strategic entry point for sales conversations around local manufacturing support, clinical trial infrastructure, and supply chain solutions tailored to East Africa.

Funding & Scale With substantial revenue in the broad, nonprofit sector (0.5–1B) and government funding from multiple nations, there is potential to present value through capacity-building programs, data analytics services, real-world evidence generation, and funded vaccine development initiatives that align with donor-driven agendas.